Jikei Nateglinide and Arbs for Vascular Intervention Study

Jikei Nateglinide and Arbs for Vascular Intervention Study - J-NAVI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001080

Enrollment

100

Registered

2008-03-15

Start date

2007-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Nateglinide 30 to 90mg per times and Valsartan 80mg Nateglinide 30 to 90mg per times and Telmisartan 40mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients with hypertension gave written informed consent to participate in the study,and treated with Nateglinide and ARB.

Exclusion criteria

Exclusion criteria: 1)Patients with severe heart disease 2)Patients with severe liver dysfunction 3)Patients with poor glycemic controls(glycated hemoglobin >8.0%) 4)Drug allegy to ARB 5)Patients with hemodialysis 6)Pregnant or possibility of pregnant 7)Patients that treated with pioglitazone within 6 months 8)Patients with renal dysfunction(serum creatinine>3.0mg/dl) 9)Other patients judged inappropriate for the study by the investigators

Design outcomes

Primary

Measure	Time frame
Change in cartoid plaque volume after 24 weeks using 3-Dimensional Ultrasound	—

Countries

Japan

Contacts

Public ContactKentaro Taki

Tokyo Jikei university school of medicine Diabetes,metabolism and endocrinology

tackey@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026